(Q43700112)

English

Isoprostane 8-epi-PGF2alpha is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Co-enzyme-A-reductase inhibitor therapy

scientific article published in August 2001

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Isoprostane 8-epi-PGF2alpha is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Co-enzyme-A-reductase inhibitor therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

author name string

Sinzinger H

1

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Lupattelli G

2

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Chehne F

3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Oguogho A

4

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Furberg CD

5

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

publication date

1 August 2001

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

Journal of Clinical Pharmacy and Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

303-310

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2001.00360.X

21 January 2018

Does vitamin E beneficially affect muscle pains during HMG-Co-enzyme-A-reductase inhibitors without CK-elevation?

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2001.00360.X

21 January 2018

The isoprostanes. Current knowledge and directions for future research

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2001.00360.X

21 January 2018

Isoprostanes: potential markers of oxidant stress in atherothrombotic disease

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2001.00360.X

21 January 2018

In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2001.00360.X

21 January 2018

Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.2001.00360.X

21 January 2018

Identifiers

10.1046/J.1365-2710.2001.00360.X

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43700112&oldid=2102671790"